Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes

Vaccine
Cristiana IosefLinda J Saif

Abstract

The undesirable side effects and variable efficacy of some oral live rotavirus vaccines in infants have necessitated alternative vaccine approaches. We evaluated a recombinant RFVP2/WaVP6 rotavirus-like-particle (2/6VLP) oral vaccine, using an immunostimulating complex (ISCOM) matrix as adjuvant, in a gnotobiotic (Gn) pig model of human rotavirus (HRV) disease. The 2/6VLPs adhered to the ISCOM-matrix (2/6VLP-ISCOM ) and were antigenic, but they failed to induce protection. However, when combined with attenuated (Att) HRV for oral priming, the 2/6VLP-ISCOM vaccine was effective as a booster and induced partial protection against virulent Wa HRV. The 250 microg 2/6VLP dose was more effective than 100 microg. The highest mean numbers of IgA antibody secreting cells evaluated by ELISPOT in intestinal lymphoid tissues were in pigs receiving AttHRV+2/6VLP-ISCOM or three doses of AttHRV and were associated with the highest protection rates.

References

Jan 1, 1987·Medical Microbiology and Immunology·B WahrenB Morein
Oct 1, 1995·European Journal of Immunology·K J MaloyA M Mowat
Sep 1, 1996·The Journal of Infectious Diseases·T Vesikari, J Joensuu
Apr 10, 1997·Cellular Immunology·A SjölanderK Lövgren Bengtsson
Jun 1, 1997·Vaccine·S C ChenJ E Herrmann
May 12, 1998·The Pediatric Infectious Disease Journal·J JoensuuT Vesikari
Sep 2, 1998·Proceedings of the National Academy of Sciences of the United States of America·J L HeeneyD Davis
Oct 16, 1999·Scandinavian Journal of Immunology·S BehboudiM C Villacres-Eriksson
Oct 16, 1999·Veterinary Immunology and Immunopathology·L A van PinxterenD R Snodgrass
Oct 20, 1999·Methods : a Companion to Methods in Enzymology·B Morein, K L Bengtsson
Feb 24, 2001·The New England Journal of Medicine·T V MurphyUNKNOWN Rotavirus Intussusception Investigation Team
Apr 20, 2001·Scandinavian Journal of Immunology·C K Lee

❮ Previous
Next ❯

Citations

Mar 8, 2005·Immunology and Cell Biology·Megan T SandersMartin J Pearse
Jul 18, 2008·Journal of Clinical Microbiology·P J CollinsH O'Shea
Aug 28, 2004·Journal of Virology·John W A RossenAlexandra W C Einerhand
Jul 25, 2012·Therapeutic Delivery·Thanigaivel Shanmugam, Rinti Banerjee
Apr 4, 2013·Molecular Pharmaceutics·Gaëlle VacherGerrit Borchard
May 20, 2009·Vaccine·Hong-Xiang SunYi-Ping Ye
Sep 28, 2010·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Emily M Plummer, Marianne Manchester
Aug 9, 2007·Expert Opinion on Drug Delivery·Dmytro S SilinAldar S Bourinbaiar
Aug 31, 2013·Veterinary Immunology and Immunopathology·Caroline FossumKarin Lövgren Bengtsson
Nov 12, 2014·Annual Review of Animal Biosciences·Kuldeep S ChatthaLinda J Saif
Jan 24, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sukumar KandasamyLinda J Saif
Sep 10, 2016·World Journal of Gastroenterology : WJG·Jin-Tao LiYu-Zhang Wu
May 24, 2017·Veterinary Research·Viktor AhlbergCaroline Fossum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.